Skip to content
HowShorted

Iovance Biotherapeutics, Inc. short interest in 2021

In 2021, Iovance Biotherapeutics, Inc.'s disclosed short interest ran from 10.46% of shares outstanding on 15 Jan 2021 to 7.95% on 31 Dec 2021, a change of -2.51 percentage points. The year's high was 14.61% on 28 May 2021 and its low 7.95% on 31 Dec 2021, averaging 10.97% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.52 days on 12 Feb 2021. Full history: Iovance Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Iovance Biotherapeutics, Inc. in 2021

2021 in figures

Start of year
10.46% (15 Jan 2021)
End of year
7.95% (31 Dec 2021)
Change
-2.51 pp
High
14.61% (28 May 2021)
Low
7.95% (31 Dec 2021)
Average
10.97%
Highest days to cover
16.52 (12 Feb 2021)
SEC filings marked
8

Every report in 2021

Iovance Biotherapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202110.46%13.58
29 Jan 20219.58%11.52
12 Feb 20218.71%16.52
26 Feb 20219.53%11.1310-K filed, results (8-K)
15 Mar 202110.14%7.80
31 Mar 202114.53%8.12
15 Apr 202113.66%11.15
30 Apr 202112.92%11.93
14 May 202113.16%8.6210-Q filed, results (8-K)
28 May 202114.61%2.22
15 Jun 202113.55%5.22
30 Jun 202111.60%7.12
15 Jul 202111.68%10.23
30 Jul 202111.28%11.41
13 Aug 202111.08%10.1610-Q filed, results (8-K)
31 Aug 202110.86%12.23
15 Sep 202110.14%10.55
30 Sep 20219.58%10.94
15 Oct 20219.94%13.07
29 Oct 20219.71%13.96
15 Nov 202110.07%6.2310-Q filed, results (8-K)
30 Nov 20219.95%8.43
15 Dec 20218.54%7.35
31 Dec 20217.95%7.68

See also: Iovance Biotherapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.